Gene therapy, early promises, subsequent problems, and recent breakthroughs

Advanced Pharmaceutical Bulletin

Volumn 3, Issue 2, 2013, Pages 249-255

  Soofiyani, Saeideh Razi ^a,b   Baradaran, Behzad ^a,b   Lotfipour, Farzaneh ^b   Kazemi, Tohid ^b   Mohammadnejad, Leila ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Gene therapy; Non viral vectors; Recombinant DNA technology; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR;

ARTICLE; CLINICAL TRIAL (TOPIC); ELECTROPORATION; EX VIVO GENE TRANSFER; GENE GUN IMMUNIZATION; GENE THERAPY; GENE VECTOR; GERM LINE GENE THERAPY; HUMAN; HYDRODYNAMICS; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; INTERLEUKIN 2 RECEPTOR GAMMA GENE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; SEVERE COMBINED IMMUNODEFICIENCY; SOMATIC GENE THERAPY; ULTRASOUND; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84885753625     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2013.041     Document Type: Article

References (75)

1. Lehtolainen P, Laukkanen MO, Ylä-Herttuala S. Biotechnology. in: Gene therapy. Vol. XI, Encyclopedia of Life Support Systems (EOLSS), 2005. Available at: [http://www.eolss.net].
2. Ehmann WC, Rabkin CS, Eyster ME, Goedert JJ. Thrombocytopenia in HIV-infected and uninfected hemophiliacs. Multicenter Hemophilia Cohort Study. Am J Hematol 1994;54(4):296-300.
3. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, Mcclelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24(3):257-61.
4. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001;344(23):1773-9.
5. Culver K. Gene Therapy-A Handbook for Physicians. New York: Mary Ann Liebert Inc; 1994.
6. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995;270(5235):475-80.
7. Friedmann T. A brief history of gene therapy. Nat Genet 1992;2(2):93-8.
8. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science 1972;175(4025):949-55.
9. Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011;29(2):121-8.
10. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 2004;6(6):597-602.
11. Cavazzana-Calvo M, Hacein-Bey S, Yates F, De Villartay JP, Le Deist F, Fischer A. Gene therapy of severe combined immunodeficiencies. J Gene Med 2001;3(3):201-6.
12. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323(9):570-8.
13. J Gene Med. Gene Therapy Clinical Trials Database. Available from: http://www.wiley.com/legacy/wileychi/genmed/clinical.
14. Strachan T, Read AP. Human Molecular Genetics. 3rd ed. New york: Garland Publishing; 2004.
15. Akhtar N, Akram M, Asif HM, Usmanghani K, Ali Shah SM, Rao SA, et al. Gene therapy, a review article. J Med Plant Res 2011;5(10):1812-7.
16. Brenner MK. Human somatic gene therapy: progress and problems. J Intern Med 1995;237(3):229-39.
17. Berg P, Singer MF. The recombinant DNA controversy: twenty years later. Proc Nat Acad Sci USA 1995; 92:9011-3.
18. Gould DJ, Favorov P. Vectors for the treatment of autoimmune disease. Gene Ther 2003;10(10):912-27.
19. Mountain A. Gene therapy: the first decade. Trends Biotechnol 2000;18(3):119-28.
20. Canver MC. Evaluation of the Clinical Success of Ex Vivo and In Vivo Gene Therapy. J Young Invest 2009;19(7):1-10.
21. Templeton, NS. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. New York: CRC Press; 2008.
22. Gregory-Evans K, Bashar AM, Tan M. Ex vivo gene therapy and vision. Curr Gene Ther 2012;12(2):103-15.
23. Rejali D, Lee VA, Abrashkin KA, Humayun N, Swiderski DL, Raphael Y. Cochlear implants and ex vivo BDNF gene therapy protect spiral ganglion neurons. Hear Res 2007;228(1-2):180-7.
24. Lafont A, Guerot C, Lemarchand P. Prospects for gene therapy in cardiovascular disease. Eur Heart J 1996;17(9):1312-7.
25. Crystal RG. The gene as the drug. Nat Med 1995;1:15-7.
26. Nabel EG. Gene transfer for vascular diseases. Atherosclerosis 1995;118(26):51-6.
27. Muller DW. Gene therapy for cardiovascular disease. Br Heart J 1994;72(4):309-12.
28. Crystal RG. The Gordon Wilson Lecture. In vivo gene therapy: a strategy to use human genes as therapeutics. Trans Am Clin Climatol Assoc 1995;106:87-99.
29. Wilson JM. Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest 1995;96(6):2547-54.
30. Cotrim AP, Baum BJ. Gene Therapy: Some History, Applications, Problems, and Prospects. Toxicol Pathol 2008;36:97-103.
31. Friedmann T. The Development of Human Gene Therapy. New York: Cold Spring Harbor Laboratory Press; 1999.
32. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7(1):33-40.
33. Zhang C, Wang QT, Liu H, Zhang ZZ, Huang WL. Advancement and prospect of tumor gene therapy. Chinese J Cancer Res 2011;30(3):182-8.
34. Miller N, Vile R. Targeted vectors for gene therapy. FASEB J 1995;9(2):190-9.
35. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005;74:711-38.
36. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004;94(1):1-14.
37. Kaneda Y, Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci 2006;97(5):348-54.
38. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005;74:711-38.
39. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999;10(5):440-7.
40. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann N Y Acad Sci 1994;716:90-101; discussion -3.
41. Kovesdi I, Brough DE, Bruder JT, Wickham TJ. Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997;8(5):583-9.
42. Muzyczka, N. Use of adeno-associated virus as a general tranduction vector for mammalian cells. Curr Top Microbiol Immunol 1992;158:97-129.
43. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics reponsible for long-term episomal persistence in muscle tissue. J Virol 1999;73(1):8568-77.
44. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999;73(7):5438-47.
45. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winther B, et al. The kinetics of rAAV integration in the liver. Nat Genet 1998;19(1):13-5.
46. Coffin J, Hughes SH, Varmus HE. Retroviruses. New York: Cold Spring Harbor Laboratory Press; 2000.
47. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000;2(5):308-16.
48. Bukrinsky MI, Haffar OK. HIV-1 nuclear import: in search of a leader. Front Biosci 1999;4:D772-81.
49. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272(5259):263-7.
50. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007;9:257-88.
51. Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006;17(9):890-7.
52. Andre F, Mir LM. DNA electro transfer: its principles and an updated review of its therapeutic applications. Gene Ther 2004;11(Suppl 1):S33-42.
53. Newman CM, Bettinger T. Gene therapy progress and prospects: ultrasound for gene transfer. Gene Ther 2007;14(6):465-75.
54. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev 2008;60(10):1193-208.
55. Haag P, Frauscher F, Gradl J, Seitz A, Schafer G, Lindner JR, et al. Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol 2006;102(1-5):103-13.
56. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6(7):1258-66.
57. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993;90(24):11478-82.
58. Kohn DB, Sadelain M, Dunbar C, BodineD, Kiem HP, Candotti F, et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003;8(2):180-7.
59. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995;270(5235):475-80.
60. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-58.
61. Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M. LM02 and gene therapy for severe combined immunodeficiency. N Engl J Med 2004;350(24):2526-7.
62. Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998;5(1):52-63.
63. Gottesman MM. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther 2003;10(7):501-8.
64. Nettelbeck DM. Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003;14(8):577-84.
65. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997;8(1):37-44.
66. Zsengeller Z, Otake K, Hossain SA, Berclaz PY, Trapnell BC. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol 2000;74(20):9655-67.
67. Yasuda K, Ogawa Y, Kishimoto M, Takagi T, Hashida M, Takakura Y. Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem Biophys Res Commun 2002;293(1):344-8.
68. Yi AK, Krieg AM. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol 1998;161(9):4493-7.
69. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3(8):849-54.
70. Chirmule N, Hughes JV, Gao GP, Raper SE, Wilson JM. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998;72(7):6138-45.
71. Molinier-Frenkel V, Gahery-Segard H, Mehtali M, Le Boulaire C, Ribault S, Boulanger P, et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000;74(16):7678-82.
72. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A 1998;95(19):11377-82.
73. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6(9):1574-83.
74. Cichon G, Boeckh-Herwig S, Schmidt HH, Wehnes E, Muller T, Pring-Akerblom P, et al. Complement activation by recombinant adenoviruses. Gene Ther 2001;8(23):1794-800.
75. Bessis N, Garciacozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004;11 Suppl 1:S10-7.